BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cipla Ltd. delivered a better-than-expected Q3 FY22 performance, led by robust growth in the domestic formulation segment, steadily improving sales in North America, and better operating leverage.
This was partly offset by a momentary slowdown in active pharma ingredient sales in the developed markets.
We raise our FY22E/FY23E/FY24E earnings per share estimate by 3%/6%/4%, factoring in-
Cipla's market share gains in already launched Abbreviated New Drug Applications and upcoming potential new launches, such as Lanreotide,
strong growth in anchor consumer brands in India/South Africa, and
moderation in the API business outlook.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR